BioSpace News Archive

Since December 2019, the world is facing the new coronavirus challenge, and measures have been taken against the outbreak. The continuously increasing number of prevalence of coronavirus infected patients and the death cases clearly show, that there is no therapy against coronaviruses yet.

BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced a collaboration with the New York City Health and Hospital Corporation (NYC Health + Hospitals) to provide coronavirus disease 2019 (COVID-19) testing

To assist healthcare organizations in their response to COVID-19, Orbita today announced its new Orbita COVID-19 Virtual Assistant, a turnkey chatbot that can be readily integrated into existing websites to improve access to coronavirus-specific question-answering and screening tools.

Diffusion Pharmaceuticals Inc. (Nasdaq: DFFN), a cutting-edge biotechnology company developing new treatments for life-threatening medical conditions by improving the body’s ability to bring oxygen to the areas where it is needed most, today reported financial results for 2019 and provided a business update.

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced precautionary measures the company is taking to help protect the health and safety of its employees, partners, and the healthcare workers and patients involved in ongoing clinical studies of Arrowhead’s investigational medicines

NANOBIOTIX (Paris:NANO) (Euronext : NANO – ISIN: FR0011341205 – the ‘‘Company’’), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced its audited consolidated results for the fiscal year ending December 31, 2019:

On March 16, FDA updated its guidance on COVID-19 testing to allow clinical labs to create and perform COVID-19 tests without pursuing FDA emergency use authorization (EUA)

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“the Company”), the leading developer of spider silk based fibers, announces the rescheduling of the upcoming press conference.

Circle Pharma, Inc., a macrocycle drug discovery and development company focused on intractable cancer targets, announced that it has raised $45 million in a Series B financing.

Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body, provided a business update for the fourth quarter and full year 2019.